drugset / Trial / NCT02276768

Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method

NCT02276768 ↗

Phase 1 Completed 90 enrolled gicare Pharma Inc. Algorithme Pharma Inc · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates colonic analgesia by comparing two novel formulations, GIC-1001 and GIC-1002 with placebo using a barostat distender. The healthy male and female volunteers randomized to one of 5 possible treatments will be exposed to rectal distension following a 3-day treatment TID. The barostat methodology is a well-established and validated way to assess visceral pain. Visceral pain will be evaluated during exposure to varying distender pressures using a visual analog scale.

Timeline

Start
2014-10
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator GIC-1002 Unknown 345 mg Oral
Comparator GIC-1002 Unknown 460 mg Oral
Subject trimebutine 3-thiocarbamoylbenzenesulfonate Small molecule 375 mg Oral
Subject trimebutine 3-thiocarbamoylbenzenesulfonate Small molecule 500 mg Oral

Indications